Skip to main content


(ProFocal is not available and undergoing global clinical investigation)

One in 6 men will be diagnosed with Prostate Cancer in their lifetime. It is the second commonest cancer in men. Curative treatment will be recommended in 2 out of 3 men. The current options available are either surgery or radiotherapy. Surgery and radiotherapy are curative but are often associated with significant morbidity impacting the quality of life of the individual.

“Benign prostatic hyperplasia” affects about 50 percent of men between the ages of 51 and 60 and up to 90 percent of men older than 80 globally. Benign prostatic hyperplasia (BPH) is the most common benign tumour in men – affecting the ability to urinate normally. Men with BPH often need medical or surgical management from a urologist at some point through the lifetime of their disease. There are many surgical options available for men with BPH, ranging from invasive open surgery, transurethral to minimally invasive Focal laser therapy. Although BPH is not cancerous, it can progress to cause lower urinary tract symptoms (LUTS) that can impact a man’s quality of life and physical health. Most surgical interventions have associated side effects which have been shown to be comparably less with focal laser therapy.

Focal Therapy only targets the prostate lesions that can be seen through MRI or Ultrasound scan. The option of surgery or alternative treatments is always possible after Focal Therapy and treatment is repeatable if necessary. With Focal Therapy men are not limited to a single treatment option, it opens up more choices for patients.

The ProFocal System is a dual component precision surgical tool. It is designed by Surgeons for Surgeons to target and ablate prostate tissue.